Polycythemia classification: Difference between revisions

Jump to navigation Jump to search
 
(23 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Polycythemia}}
{{Polycythemia}}
{{CMG}}
{{CMG}}{{AE}}{{Debduti}}
 
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.


==Overview==
==Overview==
Mainly classified into primary and secondary causes based on the presence or absence of [[genetic mutations]] and underlying disorders.


==Classification==
==Classification==
===Primary polycythemia (Polycythemia vera)===
{{main|Polycythemia vera}}
''Primary polycythemia'', often called ''[[polycythemia vera]]'' (PCV), polycythemia rubra vera (PRV), or erythremia, occurs when excess red blood cells are produced as a result of an abnormality of the [[bone marrow]]. Often, excess [[white blood cell]]s and [[platelet]]s are also produced. Polycythemia vera is classified as a [[myeloproliferative disease]].


=== Secondary polycythemia ===
Once the diagnosis of absolute [[erythrocytosis]] has been established, red cell mass (RCM > 125% of predicted), classification can be done accordingly:<ref name="McMULLIN2008">{{cite journal|last1=McMULLIN|first1=M. F.|title=The classification and diagnosis of erythrocytosis|journal=International Journal of Laboratory Hematology|year=2008|issn=17515521|doi=10.1111/j.1751-553X.2008.01102.x}}</ref><ref name="pmid10640213">{{cite journal| author=Pearson TC| title=Diagnosis and classification of erythrocytoses and thrombocytoses. | journal=Baillieres Clin Haematol | year= 1998 | volume= 11 | issue= 4 | pages= 695-720 | pmid=10640213 | doi=10.1016/s0950-3536(98)80035-8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10640213  }}</ref><ref name="pmid7018337">{{cite journal| author=Golde DW, Hocking WG, Koeffler HP, Adamson JW| title=Polycythemia: mechanisms and management. | journal=Ann Intern Med | year= 1981 | volume= 95 | issue= 1 | pages= 71-87 | pmid=7018337 | doi=10.7326/0003-4819-95-1-71 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7018337  }}</ref><ref name="ErslevCaro2009">{{cite journal|last1=Erslev|first1=A. J.|last2=Caro|first2=J.|title=Pathophysiology and Classification of Polycythaemia|journal=Scandinavian Journal of Haematology|volume=31|issue=4|year=2009|pages=287–292|issn=0036553X|doi=10.1111/j.1600-0609.1983.tb00655.x}}</ref>
Secondary polycythemia is caused by either natural or artificial increases in the production of [[erythropoietin]] that result in an increased production of erythrocytes. In secondary polycythemia, there may be 6 to 8 million and occasionally 9 million erythrocytes per cubic millimeter of blood. A type of secondary polycythemia in which the production of erythropoietin increases appropriately is called physiologic polycythemia. Physiologic polycythemia occurs in individuals living at high altitudes, where oxygen availability is less than at sea levelMany athletes train at higher altitudes to take advantage of this effect &mdash; a legal form of [[blood doping]]. Actual polycythemia sufferers have been known to use their condition as an athletic advantage for greater stamina.  
 
*'''Primary [[erythrocytosis]]'''<ref name="pmid10646073">{{cite journal| author=Messinezy M, Pearson TC| title=The classification and diagnostic criteria of the erythrocytoses (polycythaemias) | journal=Clin Lab Haematol | year= 1999 | volume= 21 | issue= 5 | pages= 309-16 | pmid=10646073 | doi=10.1046/j.1365-2257.1999.00246.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10646073 }}</ref><ref name="pmid18823397">{{cite journal| author=McMullin MF| title=The classification and diagnosis of erythrocytosis. | journal=Int J Lab Hematol | year= 2008 | volume= 30 | issue= 6 | pages= 447-59 | pmid=18823397 | doi=10.1111/j.1751-553X.2008.01102.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18823397  }}</ref>
 
- [[Polycythemia vera]]
 
*'''Secondary [[erythrocytosis]]'''<ref name="pmid14560779">{{cite journal| author=Prchal JT| title=Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis. | journal=Hematol Oncol Clin North Am | year= 2003 | volume= 17 | issue= 5 | pages= 1151-8, vi | pmid=14560779 | doi=10.1016/s0889-8588(03)00090-x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14560779  }}</ref>


Other causes of secondary polycythemia include smoking, renal or liver tumors, or heart or lung diseases that result in [[Hypoxia (medical)|hypoxia]]. Endocrine abnormalities, prominently including pheochromocytoma and adrenal adenoma with [[Cushing's syndrome]] are also secondary causes. Athletes and bodybuilders who abuse [[anabolic steroid]]s or erythropoietin may develop secondary polycythemia.
[[Congenital]]:
          - [[Erythropoietin receptor]]-mediated
          - High oxygen affinity [[hemoglobin]]
          - [[Bisphosphoglycerate mutase|Bisphosphoglycerate]] mutase deficiency 
          - [[VHL]] ([[Von Hippel-Lindau Disease|Von Hippel-Lindau]]) [[gene mutation]] (Chuvash [[erythrocytosis]])
          - PHD2 ([[prolyl hydroxylase]] domain) mutations
          - HIF-2 alpha mutations
[[Acquired]]:
          - [[Hypoxia]] driven
              - Central [[hypoxic]] process:
                  - [[Chronic]] [[Lung disease]]
                  - Right-to-left [[cardiopulmonary]] vascular [[shunts]]
                  - [[Carbon monoxide poisoning]]
                  - Smoker's [[erythrocytosis]]
                  - [[Hypoventilation]] syndromes including [[Sleep apnea|sleep apne]]<nowiki/>a (high-altitude habitat)
              - Local [[renal]] [[hypoxia]]:
                  - [[Renal artery stenosis|Renal Artery Stenosis]]
                  - End Stage Renal Disease
                  - [[Hydronephrosis]]
                  - [[Renal cyst|Renal cysts]] ([[polycystic kidney disease]])
                  - Postrenal [[transplant]] [[Polycythemia|erythrocytosis]]
              - Pathologic EPO production:
                  - [[Tumors]]
                    - [[Cerebellum|Cerebellar]] [[hemangioblastoma]]
                    - [[Meningioma]]
                    - [[Parathyroid]] [[carcinoma]]/[[Adenoma|adenomas]]
                    - [[Hepatocellular carcinoma]]
                    - [[Renal cell cancer]]
                    - [[Pheochromocytoma]]
                    - Uterine [[Leiomyoma|leiomyomas]]
              - Exogenous EPO:
                  - Drug associated
                    - EPO administration
                    - [[Androgen]] administration
[[Idiopathic]] erythrocytosis <ref name="pmid967201">{{cite journal |vauthors=Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L |title=Polycythemia vera: stem-cell and probable clonal origin of the disease |journal=N Engl J Med |volume=295 |issue=17 |pages=913–6 |date=October 1976 |pmid=967201 |doi=10.1056/NEJM197610212951702 |url=}}</ref><ref name="pmid20008248">{{cite journal| author=McMullin MF| title=Idiopathic erythrocytosis: a disappearing entity. | journal=Hematology Am Soc Hematol Educ Program | year= 2009 | volume=  | issue=  | pages= 629-35 | pmid=20008248 | doi=10.1182/asheducation-2009.1.629 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20008248  }}</ref><ref name="pmid11317965">{{cite journal| author=Pearson TC, Messinezy M| title=Idiopathic erythrocytosis, diagnosis and clinical management. | journal=Pathol Biol (Paris) | year= 2001 | volume= 49 | issue= 2 | pages= 170-7 | pmid=11317965 | doi=10.1016/s0369-8114(00)00025-0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11317965  }}</ref>


==References==
==References==
{{reflist|2}}


{{Reflist|2}}
[[Category:Hematology]]
[[Category:Needs Content]]
[[Category:Emergency medicine]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Blood disorders]]
[[Category:Blood disorders]]
[[Category:Hematology|Polycythemia]]

Latest revision as of 17:26, 25 February 2021

Polycythemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia classification

CDC on Polycythemia classification

Polycythemia classification in the news

Blogs on Polycythemia classification

Directions to Hospitals Treating Polycythemia

Risk calculators and risk factors for Polycythemia classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]

Overview

Mainly classified into primary and secondary causes based on the presence or absence of genetic mutations and underlying disorders.

Classification

Once the diagnosis of absolute erythrocytosis has been established, red cell mass (RCM > 125% of predicted), classification can be done accordingly:[1][2][3][4]

- Polycythemia vera

Congenital:

         - Erythropoietin receptor-mediated
         - High oxygen affinity hemoglobin
         - Bisphosphoglycerate mutase deficiency  
         - VHL (Von Hippel-Lindau) gene mutation (Chuvash erythrocytosis)
         - PHD2 (prolyl hydroxylase domain) mutations
         - HIF-2 alpha mutations

Acquired:

         - Hypoxia driven
             - Central hypoxic process:
                 - Chronic Lung disease
                 - Right-to-left cardiopulmonary vascular shunts
                 - Carbon monoxide poisoning
                 - Smoker's erythrocytosis
                 - Hypoventilation syndromes including sleep apnea (high-altitude habitat)
             - Local renal hypoxia:
                 - Renal Artery Stenosis
                 - End Stage Renal Disease
                 - Hydronephrosis
                 - Renal cysts (polycystic kidney disease)
                 - Postrenal transplant erythrocytosis
             - Pathologic EPO production:
                 - Tumors
                    - Cerebellar hemangioblastoma
                    - Meningioma
                    - Parathyroid carcinoma/adenomas
                    - Hepatocellular carcinoma
                    - Renal cell cancer
                    - Pheochromocytoma
                    - Uterine leiomyomas
              - Exogenous EPO:
                  - Drug associated 
                    - EPO administration
                    - Androgen administration

Idiopathic erythrocytosis [8][9][10]

References

  1. McMULLIN, M. F. (2008). "The classification and diagnosis of erythrocytosis". International Journal of Laboratory Hematology. doi:10.1111/j.1751-553X.2008.01102.x. ISSN 1751-5521.
  2. Pearson TC (1998). "Diagnosis and classification of erythrocytoses and thrombocytoses". Baillieres Clin Haematol. 11 (4): 695–720. doi:10.1016/s0950-3536(98)80035-8. PMID 10640213.
  3. Golde DW, Hocking WG, Koeffler HP, Adamson JW (1981). "Polycythemia: mechanisms and management". Ann Intern Med. 95 (1): 71–87. doi:10.7326/0003-4819-95-1-71. PMID 7018337.
  4. Erslev, A. J.; Caro, J. (2009). "Pathophysiology and Classification of Polycythaemia". Scandinavian Journal of Haematology. 31 (4): 287–292. doi:10.1111/j.1600-0609.1983.tb00655.x. ISSN 0036-553X.
  5. Messinezy M, Pearson TC (1999). "The classification and diagnostic criteria of the erythrocytoses (polycythaemias)". Clin Lab Haematol. 21 (5): 309–16. doi:10.1046/j.1365-2257.1999.00246.x. PMID 10646073.
  6. McMullin MF (2008). "The classification and diagnosis of erythrocytosis". Int J Lab Hematol. 30 (6): 447–59. doi:10.1111/j.1751-553X.2008.01102.x. PMID 18823397.
  7. Prchal JT (2003). "Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis". Hematol Oncol Clin North Am. 17 (5): 1151–8, vi. doi:10.1016/s0889-8588(03)00090-x. PMID 14560779.
  8. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L (October 1976). "Polycythemia vera: stem-cell and probable clonal origin of the disease". N Engl J Med. 295 (17): 913–6. doi:10.1056/NEJM197610212951702. PMID 967201.
  9. McMullin MF (2009). "Idiopathic erythrocytosis: a disappearing entity". Hematology Am Soc Hematol Educ Program: 629–35. doi:10.1182/asheducation-2009.1.629. PMID 20008248.
  10. Pearson TC, Messinezy M (2001). "Idiopathic erythrocytosis, diagnosis and clinical management". Pathol Biol (Paris). 49 (2): 170–7. doi:10.1016/s0369-8114(00)00025-0. PMID 11317965.